Capital Royalty Establishes Strategic Advisory Committee
Pharmaceutical Industry Veteran and Pioneer Sidney Taurel Joins ...
Capital Royalty Promotes Mike Weinmann to Managing Director
Capital Royalty Strengthens Royalty Investment Team With Three New ...
Capital Royalty Enhances Royalty Investment Team With New Principals ...
News
Capital Royalty Purchases Interest in Royalty Portfolio
In the fourth quarter of 2009, a global pharmaceutical company sold a royalty interest in two leading drugs targeting different therapeutic areas to a consortium of investors (including Capital Royalty) for more than $100 million.
Royalty Bond Primer for Issuers
Royalty bonds are a viable alternative source of capital for companies and institutions seeking to monetize royalty entitlements. Specifically, royalty bonds are a source of non-dilutive debt financing with a competitive cost of capital for issuers, provide a means of managing risk without eliminating exposure to a royalty stream, and have favorable tax and accounting treatment. To date, over $2 billion of royalty bonds have been structured, issued, and traded by royalty investors including Capital Royalty.